NTLA: Utang marang Ekuitas intelliatx.com

intelliatx.com (NTLA) - logo korporat

High R&D costs and uncertainty regarding CRISPR side effects are weighing on Intellia Therapeutics (NTLA) margins, although partnerships with industry behemoths maintain stability. Intellia Therapeutics (NTLA) aims for the complete cure of hereditary pathologies via single-dose injections. However, geopolitical fractures and sanctions are hindering global trials. The debt-to-equity ratio history demonstrates the credit load, where the value 0.10 shows the current magnitude.

NTLA: Total Utang marang Modal intelliatx.com 04.07.2022 - 31.10.2026

Rincian analitis perusahaan Intellia Corp (NTLA)

- rega saham lan konsensus proyeksi valuasi:
Rega saham Intellia Therapeutics, Inc.|NTLA - Prakiraan gabungan firma investasi
- informasi kapitalisasi pasar:
Nilai pasar Intellia Therapeutics|NTLA - Nilai Bisnis
- rincian nilai buku perusahaan:
Nilai Buku saben Saham Intellia Therapeutics|NTLA - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku intelliatx.com|NTLA - Gunggung Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Ekuitas Intellia Therapeutics|NTLA - Rasio utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Intellia Therapeutics|NTLA - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Intellia Therapeutics|NTLA - Utang jangka dawa|Utang jangka cendhak perusahaan Intellia Therapeutics|Likuiditas cepet intelliatx.com
- informasi bathi lan kelipatan valuasi:
NTLA - Bathi resik perusahaan
Pambiji fundamental:Intellia Therapeutics, Inc., NTLA
Barang utama intelliatx.com

Investors use this ratio to assess the financial autonomy and debt sustainability of a business. The metric is calculated as the ratio of total liabilities to equity, determining the degree of dependence on external borrowings. For Intellia Therapeutics (NTLA), a low debt load confirms the strategic precision of management in advancing CRISPR programs. Controlling leverage minimizes bankruptcy risks. By analyzing changes in the total debt-to-equity ratio, one can evaluate the pace of the company's financial recovery.

Pesaing Intellia Therapeutics

TEM (tempus.com) - Total Utang marang Modal|Rasio Utang marang Ekuitas QGEN (Qiagen NV)|Utang marang Ekuitas Ionis Pharma (IONS)|Repligen Inc. - Rasio Utang marang Ekuitas|Total Utang marang Modal RNA (Avidity Biosciences)|Total Utang marang Modal crisprtx.com CRSP|GeneDx - Total Utang marang Modal|Koefisien Total Utang marang Modal Ultragenyx Pharmaceutical Inc. RARE|Beam Therapeutics Corp (BEAM) - Utang marang Ekuitas|Rasio Utang marang Ekuitas SRPT|Rasio Total Utang marang Ekuitas TWST|TXG (10xgenomics.com) - Utang Agregat marang Modal|Total Utang marang Modal STOK|BLFS - Utang marang Modal|Utang marang Ekuitas Wave Life Sciences Corp WVE|Maze Therapeutics Corp - Utang marang Ekuitas|SION - Utang marang Ekuitas|PRME: Utang marang Ekuitas|TSHA: Total Utang marang Modal|QURE - Koefisien Total Utang marang Modal|MGTX (MeiraGTx PLC) - Total Utang marang Modal|Total Utang marang Modal REGENXBIO Corp|Rasio Total Utang marang Ekuitas SLDB (Solid Biosciences Inc.)|OCGN (ocugen.com) - Rasio Kabeh Utang marang Dana Pribadi|PacBio - Rasio Total Utang marang Ekuitas|Utang Agregat marang Modal BNTC (Benitec Biopharma Inc)|Design Pharma - Total Utang marang Modal|Rasio Kabeh Utang marang Dana Pribadi RCKT (Rocket Corp)|FDMT: Total Utang marang Modal|Utang marang Modal Lexeo Therapeutics, Inc. (LXEO)|Utang marang Ekuitas Korro Bio Inc.|EDIT: Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal SLN|Total Utang marang Modal proqr.com (PRQR)|Utang marang Ekuitas Codexis CDXS|SGMO (sangamo.com) - Utang Agregat marang Ekuitas|Nautilus Biotechnology Inc - Total Utang marang Modal|Utang marang Modal Metagenomi Inc.|DTIL (Precision BioSciences, Inc.) - Rasio Total Utang marang Ekuitas|Generation Bio (GBIO) - Total Utang marang Modal|Rasio Total Utang marang Ekuitas BOLD|XCUR (Exicure Corp) - Utang Agregat marang Modal|Total Utang marang Modal IMNN|Koefisien Total Utang marang Modal phiopharma.com|Total Utang marang Modal MBIO (Mustang Bio)|RNAZ - Rasio Total Utang marang Ekuitas|BNGO - Utang marang Ekuitas|Koefisien Total Utang marang Modal adnas.com APDN|bluebird bio (BLUE) - Utang marang Ekuitas|Rasio Utang marang Ekuitas IPA|Rasio Total Utang marang Ekuitas OMGA|OMIC (Singular Genomics Corp) - Utang Agregat marang Modal|Utang marang Ekuitas Regulus Therapeutics (RGLS)|Utang marang Ekuitas SYRS (syros.com)|Total Utang marang Modal TBIO (Telesis Bio)|Total Utang marang Modal TRACON Pharmaceuticals Inc. TCON|Unity Bio - Total Utang marang Modal